{"id":"F2019L00012","name":"Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 12 of 2019)","slug":"statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":98655,"registerId":"commonwealth-F2019L00012-current","compilationNumber":null,"startDate":"2026-04-02","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 12 of 2019)","content":"![Commonwealth Coat of Arms](image.001.png)\n\nStatement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 12 of 2019)\n\nmade under subsection 196B(3) of the\n\nVeterans' Entitlements Act 1986\n\nCompilation No. 2\n\nCompilation date: 30 May 2022\n\nIncludes amendments up to: Amendment Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 54 of 2022) (F2022L00674)\n\nThe day of commencement of this Amendment Statement of Principles concerning hypopituitarism is 30 May 2022.\n\nAbout this compilation\n\nThis compilation\n\nThis is a compilation of the Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 12 of 2019) that shows the text of the law as amended and in force on 30 May 2022.\n\nThe notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.\n\nUncommenced amendments\n\nThe effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.\n\nApplication, saving and transitional provisions for provisions and amendments\n\nIf the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.\n\nModifications\n\nIf the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.\n\nSelf‑repealing provisions\n\nIf a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.\n\nContents\n\n1 Name\n\n3 Authority\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\nEndnotes\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\n  \n\n1 Name\n\nThis is the Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 12 of 2019).\n\n3 Authority\n\nThis instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n5 Application\n\nThis instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about hypopituitarism and death from hypopituitarism.\n\nMeaning of hypopituitarism\n\n(2) For the purposes of this Statement of Principles, hypopituitarism:\n\n(a) means an endocrine disease characterised by biochemically-documented deficient production of one or more pituitary hormones, sufficient to produce clinical symptoms and signs, or to necessitate pituitary hormone replacement therapy, as a result of loss or damage to pituitary hormone-secreting cells in the pituitary gland, hypothalamus or pituitary stalk; and\n\n(b) excludes heritable and congenital forms of hypopituitarism.\n\n> Note 1: Pituitary hormones are growth hormone, follicle stimulating hormone (FSH), luteinising hormone, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), prolactin, oxytocin and antidiuretic hormone (ADH).\n\n> Note 2: The clinical presentation of hypopituitarism can be acute or chronic, and the order and amount of the specific hormone deficiency depends on the nature and speed of damage to the hypothalamic–pituitary region.\n\n(3) While hypopituitarism attracts ICD‑10‑AM code E23.0, in applying this Statement of Principles the meaning of hypopituitarism is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from hypopituitarism\n\n(5) For the purposes of this Statement of Principles, hypopituitarism, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's hypopituitarism.\n\n> Note: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nOn the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that hypopituitarism and death from hypopituitarism can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.\n\n> Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must exist before it can be said that, on the balance of probabilities, hypopituitarism or death from hypopituitarism is connected with the circumstances of a person's relevant service:\n\n(1) having an autoimmune disorder involving the pituitary gland at the time of the clinical onset of hypopituitarism;\n\n(2) having a disorder from the specified list of infiltrative, inflammatory or granulomatous disorders, involving the pituitary gland or hypothalamus, at the time of the clinical onset of hypopituitarism;\n\n> Note: specified list of infiltrative, inflammatory or granulomatous disorders is defined in the Schedule 1 - Dictionary.\n\n(3) having infection with human immunodeficiency virus before the clinical onset of hypopituitarism;\n\n(4) having a viral, bacterial, fungal or protozoal infection of the pituitary gland, hypothalamus, brain or cerebral meninges, within the five years before the clinical onset of hypopituitarism;\n\n(5) having Hantavirus haemorrhagic fever with renal syndrome within the five years before the clinical onset of hypopituitarism;\n\n> Note: Hantavirus haemorrhagic fever with renal syndrome is defined in the Schedule 1 \\- Dictionary.\n\n(6) having moderate to severe traumatic brain injury within the ten years before the clinical onset of hypopituitarism;\n\n(7) having a subarachnoid haemorrhage within the ten years before the clinical onset of hypopituitarism;\n\n(8) having haemorrhage or ischaemia involving the pituitary gland or hypothalamus within the ten years before the clinical onset of hypopituitarism;\n\n> Note: Haemorrhage or ischaemia of the pituitary gland includes pituitary apoplexy.\n\n(9) having severe peripartum or postpartum haemorrhage before the clinical onset of hypopituitarism;\n\n(10) having surgery involving the pituitary gland, or intracranial surgery, within the ten years before the clinical onset of hypopituitarism;\n\n(11) undergoing a course of therapeutic radiation for cancer, where the pituitary or hypothalamus was in the field of radiation, before the clinical onset of hypopituitarism;\n\n(12) having a space occupying lesion that involves, or impinges on, the pituitary gland or hypothalamus at the time of the clinical onset of hypopituitarism;\n\n(13) taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of hypopituitarism;\n\n> Note: immune checkpoint inhibitor is defined in the Schedule 1 \\- Dictionary.\n\n(14) for lymphocytic hypophysitis only, being pregnant within the six months before the clinical onset of hypopituitarism;\n\n> Note: lymphocytic hypophysitis is defined in the Schedule 1 \\- Dictionary.\n\n(15) having an autoimmune disorder involving the pituitary gland at the time of the clinical worsening of hypopituitarism;\n\n(16) having a disorder from the specified list of infiltrative, inflammatory or granulomatous disorders, involving the pituitary gland or hypothalamus, at the time of the clinical worsening of hypopituitarism;\n\n> Note: specified list of infiltrative, inflammatory or granulomatous disorders is defined in the Schedule 1 - Dictionary.\n\n(17) having infection with human immunodeficiency virus before the clinical worsening of hypopituitarism;\n\n(18) having a viral, bacterial, fungal or protozoal infection of the pituitary gland, hypothalamus, brain or cerebral meninges, within the five years before the clinical worsening of hypopituitarism;\n\n(19) having Hantavirus haemorrhagic fever with renal syndrome within the five years before the clinical worsening of hypopituitarism;\n\n> Note: Hantavirus haemorrhagic fever with renal syndrome is defined in the Schedule 1 \\- Dictionary.\n\n(20) having moderate to severe traumatic brain injury within the ten years before the clinical worsening of hypopituitarism;\n\n(21) having a subarachnoid haemorrhage within the ten years before the clinical worsening of hypopituitarism;\n\n(22) having haemorrhage or ischaemia involving the pituitary gland or hypothalamus within the ten years before the clinical worsening of hypopituitarism;\n\n> Note: Haemorrhage or ischaemia of the pituitary gland includes pituitary apoplexy.\n\n(23) having severe peripartum or postpartum haemorrhage before the clinical worsening of hypopituitarism;\n\n(24) having surgery involving the pituitary gland, or intracranial surgery, within the ten years before the clinical worsening of hypopituitarism;\n\n(25) undergoing a course of therapeutic radiation for cancer, where the pituitary or hypothalamus was in the field of radiation, before the clinical worsening of hypopituitarism;\n\n(26) having a space occupying lesion that involves, or impinges on, the pituitary gland or hypothalamus at the time of the clinical worsening of hypopituitarism;\n\n(27) taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of hypopituitarism;\n\n> Note: immune checkpoint inhibitor is defined in the Schedule 1 \\- Dictionary.\n\n(28) for lymphocytic hypophysitis only, being pregnant within the six months before the clinical worsening of hypopituitarism;\n\n> Note: lymphocytic hypophysitis is defined in the Schedule 1 \\- Dictionary.\n\n(29) inability to obtain appropriate clinical management for hypopituitarism.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(15) to (9)(29) apply only to material contribution to, or aggravation of, hypopituitarism where the person's hypopituitarism was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\nSchedule 1 \\- Dictionary\n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\nHantavirus haemorrhagic fever with renal syndrome means a clinical syndrome of acute shock, vascular leakage, thrombocytopaenia, hypotension and acute renal failure caused by hantaviruses from the family Bunyaviridae, which is endemic in parts of Asia and Europe. This definition includes, but is not limited to, Korean haemorrhagic fever, epidemic haemorrhagic fever and nephropathia epidemica.\n\nhypopituitarism—see subsection 7(2).\n\nimmune checkpoint inhibitor means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.\n\niron overload means an accumulation of excess iron in tissues and organs which has been confirmed by elevated ferritin or transferrin saturation levels.\n\nNote: Causes include, but are not limited to, haemochromatosis and blood transfusions.\n\nlymphocytic hypophysitis means an autoimmune condition in which the pituitary gland becomes infiltrated by lymphocytes, resulting in pituitary enlargement and impaired function.\n\nMRCA means the Military Rehabilitation and Compensation Act 2004.\n\nrelevant service means:\n\n(a) eligible war service (other than operational service) under the VEA;\n\n(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or\n\n(c) peacetime service under the MRCA.\n\n> Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\nspecified list of infiltrative, inflammatory or granulomatous disorders means:\n\n(a) a primary or metastatic neoplasm;\n\n(b) amyloidosis;\n\n(c) Castleman disease;\n\n(d) Crohn's disease;\n\n(e) eosinophilic granuloma;\n\n(f) germinoma;\n\n(g) giant cell granuloma;\n\n(h) granulomatosis with polyangiitis (Wegener granulomatosis);\n\n(i) histiocytosis;\n\n(j) iron overload;\n\n(k) sarcoidosis; or\n\n(l) Takayasu arteritis.\n\n> Note: iron overload is also defined in the Schedule 1 - Dictionary.\n\nterminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\nVEA means the Veterans' Entitlements Act 1986.\n\n> Note: Endnotes\n\n> Note: Endnote 1—About the endnotes\n\nThe endnotes provide information about this compilation and the compiled law.\n\nThe following endnotes are included in every compilation:\n\nEndnote 1—About the endnotes\n\nEndnote 2—Abbreviation key\n\nEndnote 3—Legislation history\n\nEndnote 4—Amendment history\n\nAbbreviation key—Endnote 2\n\nThe abbreviation key sets out abbreviations that may be used in the endnotes.\n\nLegislation history and amendment history—Endnotes 3 and 4\n\nAmending laws are annotated in the legislation history and amendment history.\n\nThe legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.\n\nThe amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.\n\nMisdescribed amendments\n\nA misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.\n\nIf a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.\n\n> Note: Endnote 2—Abbreviation key\n\n|                                                | o = order(s)                        |\n| ---------------------------------------------- | ----------------------------------- |\n| ad = added or inserted                         | Ord = Ordinance                     |\n| am = amended                                   | orig = original                     |\n| amdt = amendment                               | par = paragraph(s)/subparagraph(s)  |\n| c = clause(s)                                  | /sub‑subparagraph(s)                |\n| C[x] = Compilation No. x                       | pres = present                      |\n| Ch = Chapter(s)                                | prev = previous                     |\n| def = definition(s)                            | (prev…) = previously                |\n| Dict = Dictionary                              | Pt = Part(s)                        |\n| disallowed = disallowed by Parliament          | r = regulation(s)/rule(s)           |\n| Div = Division(s)                              |                                     |\n| exp = expires/expired or ceases/ceased to have | reloc = relocated                   |\n| effect                                         | renum = renumbered                  |\n| F = Federal Register of Legislation            | rep = repealed                      |\n| gaz = gazette                                  | rs = repealed and substituted       |\n| LA = Legislation Act 2003                      | s = section(s)/subsection(s)        |\n| LIA = Legislative Instruments Act 2003         | Sch = Schedule(s)                   |\n| (md) = misdescribed amendment can be given     | Sdiv = Subdivision(s)               |\n| effect                                         | SLI = Select Legislative Instrument |\n| (md not incorp) = misdescribed amendment       | SR = Statutory Rules                |\n| cannot be given effect                         | Sub‑Ch = Sub‑Chapter(s)             |\n| mod = modified/modification                    | SubPt = Subpart(s)                  |\n| No. = Number(s)                                | underlining = whole or part not     |\n|                                                | commenced or to be commenced        |\n\n> Note: Endnote 3—Legislation history\n\n| Name                                                                                                     | Registration              | Commencement    | Application, saving and transitional provisions |\n| -------------------------------------------------------------------------------------------------------- | ------------------------- | --------------- | ----------------------------------------------- |\n| Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 12 of 2019)           | 3 January 2019F2019L00012 | 28 January 2019 |                                                 |\n| Amendment Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 82 of 2021) | 29 June 2021F2021L00892   | 26 July 2021    |                                                 |\n| Amendment Statement of Principles concerning hypopituitarism (Balance of Probabilities) (No. 54 of 2022) | 3 May 2022F2022L00674     | 30 May 2022     |                                                 |\n\n> Note: Endnote 4—Amendment history\n\n| Provision affected                                              | How affected      |\n| --------------------------------------------------------------- | ----------------- |\n| Section 2……………….                                                | rep LA s 48D      |\n| Section 4……………….                                                | rep LA s 48C      |\n| Subsection 7(2)(a)…….                                           | am No. 82 of 2021 |\n| Subsection 9(13)…..…..                                          | rs No. 54 of 2022 |\n| Subsection 9(27)..……..                                          | rs No. 54 of 2022 |\n| Schedule 1 – Dictionary – immune checkpoint inhibitor……………...…. | rs No. 54 of 2022 |","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"The legislation maintains its original narrow scope focused specifically on hypopituitarism in veterans. The 2022 amendments (No. 54 of 2022) were minor technical updates to update the definition of 'immune checkpoint inhibitor' and related factors (9)(13) and (9)(27), reflecting evolving cancer treatments. The 2021 amendment (No. 82 of 2021) was a minor wording clarification in the definition. Neither expansion significantly altered the original purpose."},"complexity_factors":["29 distinct medical factors with specific timeframes (ranging from 1 year to 10 years before onset)","14 defined terms in Schedule 1 Dictionary including technical medical definitions (e.g., 'immune checkpoint inhibitor', 'lymphocytic hypophysitis')","Dual structure covering both 'clinical onset' (factors 1-14) and 'clinical worsening' (factors 15-29)","Cross-references to other Statements of Principles in section 11","Specific exclusion of hereditary/congenital forms in the definition","Reference to external medical classification system (ICD-10-AM Tenth Edition)"],"plain_english_summary":"This instrument sets when Australian veterans and current or former ADF members can claim compensation for hypopituitarism by tying entitlement to whether one of 29 specified medical causes or aggravating factors (e.g., brain injury, surgery, radiation, certain infections) led to or worsened the condition and was connected to service. It matters because it gives decision-makers a clear medical checklist and specified timeframes to ensure consistent, predictable determinations under the VEA and MRCA."},"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":true,"description":"Subsequent amendments have broadened the SOP's coverage beyond the original 2019 wording by adding contemporary treatment-related causes and clarifying definitions. Endnote and amendment history show specific amendments: subsection 7(2)(a) was amended (No. 82 of 2021) and immune checkpoint inhibitors were added to the listed factors and the dictionary (Amendment No. 54 of 2022). Concretely, the SOP now explicitly includes immunotherapy agents and updated terminology, which expands the set of clinical circumstances that can satisfy the medical test for service connection (see s 9(13) and s 9(27) as amended and the Schedule definition of \"immune checkpoint inhibitor\")."},"complexity_factors":["Relatively short instrument (11 sections plus a dictionary) but with substantive medical detail","29 distinct enumerated qualifying factors in section 9 (many repeated for onset and for clinical worsening)","Multiple explicit timing windows (1 year, 5 years, 10 years, 6 months for pregnancy), creating conditional logic","Schedule 1 contains several defined terms and a 12‑item \"specified list\" of infiltrative/inflammatory disorders","Cross-references to primary statutes (VEA and MRCA) and to other Statements of Principles (s 11)","Requirement that a qualifying factor be \"related to the relevant service\" (s 10) introduces case‑by‑case causal assessment","Amendments have recently added modern treatments (immune checkpoint inhibitors) and adjusted definitions, increasing topical coverage"],"plain_english_summary":"**What this instrument does (mechanically)\n\n- It is a \"Statement of Principles\" (SOP) made under the Veterans' Entitlements Act which sets the medical criteria used to decide whether hypopituitarism (a disorder of the pituitary gland) can be accepted as connected with a person's military or other relevant service for veterans' compensation purposes (see sections 3, 5, 7 and 9).\n\n- The SOP defines what is meant by hypopituitarism for claims purposes (biochemically documented deficiency of one or more pituitary hormones, not including congenital/heritable forms) and also covers death that a person’s hypopituitarism contributed to (s 7(2), (4)–(5)).\n\n- It lists the factual medical circumstances (\"factors\") that must exist before it can be said, on the balance of probabilities, that the condition is related to service. At least one listed factor must be present (s 9). The factors include infections, traumatic brain injury, haemorrhage/ischemia affecting the pituitary, certain surgeries, therapeutic radiation affecting the pituitary, specified inflammatory or infiltrative disorders, certain drug treatments (for example immune checkpoint inhibitors and interferons), pregnancy-related events for lymphocytic hypophysitis, and inability to obtain appropriate clinical management (s 9(1)–(29)).\n\n- Many factors have explicit time windows (for example infection, Hantavirus and some brain events within five or ten years before clinical onset or clinical worsening; see s 9(4)–(8), (18)–(22)). The SOP treats separately events that relate to the clinical onset of disease and events that relate to clinical worsening after a pre-existing condition (s 9; s 10(2)).\n\n- A listed factor only helps a claimant if that factor can be related to the person’s relevant service (s 10). If a factor points to an injury or disease already covered by another SOP, that other SOP’s factors apply as written (s 11).\n\nOfficial rationale and how the SOP is intended to be used\n\n- The Repatriation Medical Authority (RMA) records that, on the available medical evidence, it is more probable than not that hypopituitarism can be related to relevant service (s 8). The SOP is therefore the RMA’s specification of which medical facts will establish service connection for hypopituitarism under the veterans’ compensation laws.\n\nHow this operates in practice and who it affects\n\n- Who is affected: current and former members of the Defence Forces and veterans making claims under the VEA or MRCA (see s 5 and the definition of \"relevant service\").\n\n- Who decides and who pays: decision-makers in the Department of Veterans' Affairs (using this SOP as the medical test), informed by clinical records and medical evidence, determine whether a claimant has a qualifying factor. If accepted, the cost of compensation/entitlements is met under the veterans’ compensation system.\n\n- What claimants and clinicians must do differently: claimants need evidence showing one of the listed factors (for example imaging or surgical notes, records of traumatic brain injury, records of cancer radiation or immunotherapy, biochemical hormone tests, or evidence of inability to obtain care). Clinicians should document timing, biochemical confirmation of hormone deficiency and any relevant exposures or interventions that are on the SOP list.\n\nPurpose-claims tested against practical trade-offs\n\n- Claimed purpose: the SOP is presented as a medical-scientific specification of when hypopituitarism can be linked to service (s 8).\n\n- Costs and incentives: the SOP lowers the evidentiary uncertainty for claimants who can show one of the enumerated medical factors — concentrated benefit to those claimants. The fiscal cost of any additional accepted claims falls to the veterans’ compensation scheme. Administrative costs increase where assessing medical histories or establishing timing (onset versus worsening) requires detailed review.\n\n- Implementation risk and bureaucratic discretion: the SOP requires medical interpretation of timing (\"within five/ten years\") and causation (relation to service). That creates room for decision-makers to evaluate competing medical opinions. The clause that factors must be \"related to the relevant service\" (s 10(1)) preserves a discretionary nexus assessment.\n\n- Compliance burden: evidence-gathering burdens fall mostly on claimants (medical records, diagnostic tests). For clinicians, there is an increased expectation to provide clear diagnostic and treatment records.\n\n- Effects on private choice and markets: the SOP does not regulate private businesses directly. It may, however, influence behaviour in clinical practice (more detailed documentation of pituitary function after head trauma, cancer therapy or pituitary surgery). Private insurers are not directly affected by the SOP, but expanded acceptance of service connection can shift long‑run cost from private to public/compensation systems for affected veterans.\n\nConcrete substitution and unintended-consequence channels to watch\n\n- The SOP ties compensation eligibility to specific medical events and treatments. Where a listed treatment (for example immune checkpoint inhibitors or radiation with the pituitary in the field — s 9(11), (13), (25)) is common in modern care, the SOP can make treatment‑related hypopituitarism claimable if linked to service. That may increase claims that are causally related to treatment rather than to service exposures per se.\n\n- The \"inability to obtain appropriate clinical management\" factor (s 9(29)) creates a route for claims where delayed or absent care plausibly contributed to disease progression; assessing this will be fact‑specific and may impose evidentiary difficulty on decision-makers.\n\n- The SOP excludes congenital or heritable hypopituitarism (s 7(2)(b)), so genetic/early-life cases remain outside its scope.\n\nKey sections to look at: definition and scope of hypopituitarism (s 7(2)–(5)); list of qualifying factors and timing windows (s 9); relation-to-service requirement (s 10); interaction with other SOPs (s 11).\n\nWhy it matters\n\n- This SOP provides the binding medical checklist used by decision-makers to accept or reject claims for hypopituitarism as service‑related. For claimants, it defines which clinical histories and tests are likely to succeed. For administrators, it concentrates adjudication around the presence of listed medical factors and their connection to service, shaping evidentiary demands and program costs.\n\n"},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019","history":"/api/acts/statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019/history","analysis":"/api/acts/statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019/analysis","conflicts":"/api/acts/statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019/important-cases","documents":"/api/acts/statement-of-principles-concerning-hypopituitarism-balance-of-probabilities-no-12-of-2019/documents"}}